Nosocomial Candida infections: Epidemiology of candidaemia

Journal of Preventive Medicine and Hygiene

Volumn 47, Issue 3, 2006, Pages 119-126

  Galle F ^a   Catania, M R ^a   Liguori, G ^b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF NAPLES PARTHENOPE   (Italy)

Author keywords

Candidaemia; Epidemiology; Nosocomial infections

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; CEFTRIAXONE; CEPHALOSPORIN; IMIPENEM; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; CANDIDA; CANDIDEMIA; CANDIDIASIS; FUNGAL COLONIZATION; HOSPITAL INFECTION; HUMAN; INCIDENCE; INTENSIVE CARE UNIT; MEDICAL INSTRUMENTATION; NEUTROPENIA; REVIEW; CLASSIFICATION; CROSS INFECTION; DRUG EFFECT; GASTROINTESTINAL TRACT; MICROBIOLOGY; PATHOGENICITY; RISK ASSESSMENT; RISK FACTOR;

ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; CROSS INFECTION; GASTROINTESTINAL TRACT; HUMANS; INTENSIVE CARE UNITS; RISK ASSESSMENT; RISK FACTORS;

EID: 33847724759     PISSN: 11212233     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (97)

1. Eggimann P, Garbino J, Pittet D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis 2003;3:685-702.
2. Fridkin SK, Jarvis WR. Epidemiology of Nosocomial Fungal Infections. Clin Microbiol Rev 1996;9:499-511.
3. Verduyn Lunel FM, Meis JFGM, Voss A. Nosocomial Fungal Infections: Candidaemia. Diagn Microbiol Infect Dis 1999;34:213-20.
4. Vincent JL, Anaissie E, Bruining H, Demajo W, el-Ebiary M, Haber J, et al. Epidemiology, diagnosis and treatment of systemic Candida infection in surgical patients under intensive care. Intensive Care Med 1998;24:206-16.
5. Spaeth G, Gottwald T, Specian RD, Mainous MR, Berg RD, Deitch EA. Secretory immunoglobulin A, intestinal mucin, and mucosal permeability in nutritionally induced bacterial translocation in rats. Ann Surg 1994;220:798-808.
6. Voss A, le Noble JL, Verduyn Lunel FM, Foudraine NA, Meis JF. Candidaemia in intensive care unit patients: risk factors for mortality. Infection 1997;25:8-11.
7. Pfaller MA. Nosocomial candidiasis: emerging species, reservoirs, and modes of transmission. Clin Infect Dis 1996;22:S89-94.
8. Pfaller MA, Jones RN, Doern GV, Sader HS, Messer SA, Houston A, et al. National epidemiology of mycoses survey: a multicenter study of strain variation and antifungal susceptibility among isolates of Candida species. Diagn Microbiol Infect Dis 1998;31:289-96.
9. Strausbaugh LJ, Sewell DL, Ward TT, Pfaller MA, Heitzman T, Tjoelker R. High frequency of yeast carriage on hands of hospital personnel. J Clin Microbiol 1994;32:2299-300.
10. Beck-Sague C, Jarvis WR. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System. J Infect Dis 1993;167:1247-51.
11. Vincent JL, Anaissie E, Bruining H, Demajo W, el-Ebiary M, Haber J, et al. Epidemiology, diagnosis and treatment of systemic Candida infection in surgical patients under intensive care. Intensive Care Med 1998;24:1120-1.
12. Vincent JL, Bihari DJ, Suter PM, Bruining HA, White J, Nicolas-Chanoin MH, et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA 1995;274:639-44.
13. Emori TG, Gaynes RP. An overview of nosocomial infections, including the role of the microbiology laboratory. Clin Microbiol Rev 1993;6:428-42.
14. Schaberg DR, Culver DH, Gaynes RP. Major trends in the microbial etiology of nosocomial infection. Am J Med 1991;91:72S-75S.
15. Banerjee SN, Emori TG, Culver DH. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. National Nosocomial Infections Surveillance System. Am J Med 1991;91:86S-89S.
16. Pfaller MA, Jones RN, Messer SA, Edmond MB, Wenzel RP. National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. SCOPE Participant Group. Surveillance and Control of Pathogens of Epidemiologic. Diagn Microbiol Infect Dis 1998;30:121-9.
17. Sandven P, Bevanger L, Digranes A, Gaustad P, Haukland HH, Steinbakk M. Constant low rate of fungemia in Norway, 1991 to 1996. The Norwegian Yeast Study Group. J Clin Microbiol 1998;36:3455-9.
18. Pfaller MA, Jones RN, Doern GV, Sader HS, Hollis RJ, Messer SA. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada, and South America for the SENTRY Program. The SENTRY Participant Group. J Clin Microbiol 1998;36:1886-9.
19. Mayhall CG. Hospital Epidemiology and Infection Control. Philadelphia: Lippincott Williams & Wilkins 2004.
20. Weems JJ Jr. Candida parapsilosis: epidemiology, pathogenicity, clinical manifestations, and antimicrobial susceptibility. Clin Infect Dis 1992;14:756-66.
21. Lupetti A, Tavanti A, Davini P, Ghelardi E, Corsini V, Merusi I, et al. Horizontal Transmission of Candida parapsilosis Candidaemia in a Neonatal Intensive Care Unit. J Clin Microbiol 2002;40:2363-9.
22. Goldman M, Pottage JC, Weaver DC. Candida krusei fungemia. Report of 4 cases and review of the literature. Medicine 1993;72:143-50.
23. Jarvis WR. Epidemiology of nosocomial fungal infections, with emphasis on Candida species. Clin Infect Dis 1995;20:1526-30.
24. Pfaller MA, Diekema DJ. Role of sentinel surveillance of candidaemia: trends in species distribution and antifungal susceptibility. J Clin Microbiol 2002;40:3551-7.
25. Hobson RP. The global epidemiology of invasive Candida infections - is the tide turning? J Hosp Infect 2003;55:159-68.
26. McGowan JE Jr. Changing etiology of nosocomial bacteremia and fungemia and other hospital-acquired infections. Rev Infect Dis 1985;7:S357-70.
27. McGowan JE Jr, Barnes MW, Finland M. Bacteremia at Boston City Hospital: occurrence and mortality during 12 selected years (1935-1972), with special reference to hospital-acquired cases. J Infect Dis 1975;132:316-35.
28. Weinstein MP, Reller LB, Murphy JR, Lichtenstein KA. The clinical significance of positive blood cultures: a comprehensive analysis of 500 episodes of bacteremia and fungemia in adults. I. Laboratory and epidemiologic observations. Rev Infect Dis 1983;5:35-53.
29. Fisher-Hoch SP, Hutwagner L. Opportunistic candidiasis; an epidemic of the 1980s. Clin Infect Dis 1995;21:897-904.
30. Doczi I, Dosa E, Hajdu E, Nagy E. Aetiology and antifungal susceptibility of yeast bloodstream infections in a Hungarian university hospital between 1996 and 2000. J Med Microbiol 2002;51:677-81.
31. Luzzati R, Amalfitano G, Lazzarini L, Soldani F, Bellino S, Solbiati M, et al. Nosocomial candidaemia in non-neutropenic patients at an Italian tertiary care center. Eur J Clin Microbiol Infect Dis 2000;19:602-7.
32. Garbino J, Kolarova L, Rohner P, Lew D, Pincha P, Pittet D. Secular trends of candidaemia over 12 years in adult patients at a tertiary care hospital. Medicine 2002;81:425-33.
33. Krcmery VJ, Kovacicova G. Longitudinal 10-year prospective survey of fungaemia in Slovak Republic: trends in etiology in 310 episodes. Diagn Microbiol Infect Dis 2000;36:7-11.
34. Malani PN, Bradley SF, Little RS, Kauffman CA. Trends in species causing fungaemia in a tertiary care medical centre over 12 years. Mycoses 2001;44:446-9.
35. Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis 1999;29:239-44.
36. Hospital Infections Program, National Center for Infectious Diseases, Center for Disease Control and Prevention. National Nosocomial Infections Surveillance (NNIS) report, data summary from October 1986-April 1996, issued May 1996. Am J Infect Control 1996;24:380-8.
37. Lyytikainen O, Lumio J, Sarkkinen H, Kolho E, Kostiala A, Ruutu P. Hospital Infection Surveillance Team. Nosocomial bloodstream infections in Finnish hospitals during 1999-2000. Clin Infect Dis 2002;35:14-9.
38. Nosocomial Infection National Surveillance System. NINSS reports on surgical site infection and hospital acquired bacteraemia. Commun Dis Rep CDR Wkly 2000;10:213-6.
39. Voss A, Kluytmans JA, Koeleman JG, Spanjaard L, Vandenbroucke-Grauls CM, Verbrugh HA, et al. Occurrence of yeast bloodstream infections between 1987 and 1995 in five Dutch university hospitals. Eur J Clin Microbiol Infect Dis 1996;15:909-12.
40. Alonso-Valle H, Acha O, Garcia-Palomo JD, Farinas-Alvarez C, Fernandez-Mazarrasa C, Farinas MC. Candidaemia in a tertiary care hospital: epidemiology and factors influencing mortality. Eur J Clin Microbiol Infect Dis 2003;22:254-7.
41. McMullan R, McClurg R, Xu J, Moore JE, Millar BC, Crowe M, et al. Trends in the epidemiology of Candida bloodstream infections in Northern Ireland between January 1984 and December 2000. J Infect 2002;45:25-8.
42. Marchetti O, Bille J, Fluckiger U, Eggimann P, Ruef C, Garbino J, et al. Epidemiology of candidaemia in Swiss tertiary care hospitals: secular trends, 1991-2000. Clin Infect Dis 2004;38:311-20.
43. Klingspor L, Tornqvist E, Johansson A, Petrini B, Forsum U, Hedin G. A prospective epidemiological survey of candidaemia in Sweden. Scand J Infect Dis 2004;36:52-5.
44. Tortorano AM, Biraghi E, Astolfi A, Ossi C, Tejada M, Farina C, et al. European Confederation of Medical Mycology (ECMM) prospective survey of candidaemia: report from one Italian region. J Hosp Infect 2002;51:297-304.
45. Peman J, Canton E, Gobernado M; Spanish ECMM Working Group on Candidaemia. Epidemiology and antifungal susceptibility of Candida species isolated from blood: results of a 2-year multicentre study in Spain. Eur J Clin Microbiol Infect Dis 2005;24:23-30.
46. Boo TW, O'Reilly B, O'Leary J, Cryan B. Candidaemia in an Irish tertiary referral hospital: epidemiology and prognostic factors. Mycoses 2005;48:251-9.
47. Tortorano AM, Peman J, Bernhardt H, Klingspor L, Kibbler CC, Faure O, et al. Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis 2004;23:317-22.
48. Kossoff EH, Buescher ES, Karlowicz MG. Candidaemia in a neonatal intensive care unit: trends during fifteen years and clinical features of 111 cases. Pediatr Infect Dis J 1998;17:504-8.
49. Price MF, LaRocco MT, Gentry LO. Fluconazole susceptibilities of Candida species and distribution of species recovered from blood cultures over a 5-year period. Antimicrob Agents Chemother 1994;38:1422-7.
50. Abi-Said D, Anaissie E, Uzun O, Raad I, Pinzcowski H, Vartivarian S. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 1997;24:1122-8.
51. Cliff PR, Sandoe JA, Heritage J, Barton RC. Retrospective survey of candidaemia in hospitalized patients and molecular investigation of a suspected outbreak. J Med Microbiol 2005;54:391-4.
52. Krcmery V, Barnes AJ. Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance. J Hosp Infect 2002;50:243-60.
53. Rangel-Frausto MS, Wiblin T, Blumberg HM, Saiman L, Patterson J, Rinaldi M, et al. National epidemiology of mycoses survey (NEMIS): variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units. Clin Infect Dis 1999;29:253-8.
54. Viscoli C, Girmenia C, Marinus A, Collette L, Martino P, Vandercam B, et al. Candidaemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis 1999;28:1071-9.
55. Fraser VJ, Jones M, Dunkel J, Storfer S, Medoff G, Dunagan WC. Candidaemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin Infect Dis 1992;15:414-21.
56. Solomkin JS. Pathogenesis and management of Candida infection syndromes in non-neutropenic patients. New Horiz 1993;1:202-13.
57. Solomkin JS, Flohr AB, Quie PG, Simmons RL. The role of Candida in intraperitoneal infections. Surgery 1980;88:524-30.
58. Martino P, Girmenia C, Venditti M, Micozzi A, Santilli S, Burgio VL, et al. Candida colonisation and systemic infection in neutropenic patients. A retrospective study. Cancer 1989;64:2030-4.
59. Martino P, Girmenia C, Micozzi A, Raccah R, Gentile G, Venditti M, et al. Fungemia in patients with leukemia. Am J Med Sci 1993;306:225-32.
60. Pittet D, Monod M, Suter PM, Frenk E, Auckenthaler R. Candida colonisation and subsequent infections in critically ill surgical patients. Ann Surg 1994;220:751-8.
61. Pappu-Katikaneni LD, Rao KP, Banister E. Gastrointestinal colonisation with yeast species and Candida septicemia in very low birth weight infants. Mycoses 1990;33:20-3.
62. Richet HM, Andremont A, Tancrede C, Pico JL, Jarvis WR. Risk factors for candidaemia in patients with acute lymphocytic leukemia. Rev Infect Dis 1991;13:211-5.
63. Calandra T, Bille J, Schneider R, Mosimann F, Francioli P. Clinical significance of Candida isolated from peritoneum in surgical patients. Lancet 1989;2:1437-40.
64. Sandven P, Qvist H, Skovlund E, Giercksky KE. Significance of Candida recovered from intraoperative specimens in patients with intra-abdominal perforations. Crit Care Med 2002;30:541-7.
65. Blumberg HM, Jarvis WR, Soucie JM, Edwards JE, Patterson JE, Pfaller MA et al. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. Clin Infect Dis 2001;33:177-86.
66. Blot SI, Vandewoude KH, Hoste EA, Colardyn FA. Effects of nosocomial candidaemia on outcomes of critically ill patients. Am J Med 2002;113:480-5.
67. Edwards JE Jr, Bodey GP, Bowden RA, Buchner T, de Pauw BE, Filler SG et al. International conference for the development of a consensus on the management and prevention of severe candidal infections. Clin Infect Dis 1997;25:43-59.
68. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Risk factors for hospital-acquired candidaemia. A matched case-control study. Arch Intern Med 1989;149:2349-53.
69. Giuliano M, Barza M, Jacobus NV, Gorbach SL. Effect of broad-spectrum parenteral antibiotics on composition of intestinal microflora of humans. Antimicrob Agents Chemother 1987;31:202-6.
70. Samonis G, Anaissie EJ, Bodey GP. Effects of broad-spectrum antimicrobial agents on yeast colonisation of the gastrointestinal tracts of mice. Antimicrob Agents Chemother 1990;34:2420-2.
71. Nucci M, Colombo AL. Risk factors for breakthrough candidaemia. Eur J Clin Microbiol Infect Dis 2002;21:209-11.
72. Bow EJ, Loewen R, Cheang MS, Schacter B. Invasive fungal disease in adults undergoing remission-induction therapy for acute myeloid leukemia: the pathogenetic role of the antileukemic regimen. Clin Infect Dis 1995;21:361-9.
73. Guiot HF, Fibbe WE, van't Wout JW. Risk factors for fungal infection in patients with malignant hematologic disorders: implications for empirical therapy and prophylaxis. Clin Infect Dis 1994;18:525-32.
74. Safdar N, Maki DG. The commonality of risk factors for nosocomial colonisation and infection with antimicrobial-resistant Staphylococcus aureus, enterococcus, gram-negative bacilli, Clostridium difficile, and Candida. Ann Intern Med 2002;136:834-44.
75. Pittet D, Wenzel RP. Nosocomial bloodstream infections. Secular trends in rates, mortality, and contribution to total hospital deaths. Arch Intern Med 1995;155:1177-84.
76. Douglas LJ. Candida biofilms and their role in infection. Trends Microbiol 2003;11:30-6.
77. Wenzel RP. Nosocomial candidaemia: risk factors and attributable mortality. Clin Infect Dis 1995;20:1531-4.
78. Gudlaugsson O, Gillespie S, Lee K. Attributable mortality of nosocomial candidaemia, revisited. Clin Infect Dis 2003;37:1172-7.
79. Charles PE, Doise JM, Quenot JP, Aube H, Dalle F, Chavanet P, et al. Candidaemia in critically inpatients: difference of outcome between medical and surgical patients. Intensive Care Med 2003;29:2162-9.
80. Miller PJ, Wenzel RP. Etiologic organisms as independent predictors of death and morbidity associated with bloodstream infections. J Infect Dis 1987;156:471-7.
81. Pittet D, Li N, Woolson RF, Wenzel RP. Microbiological factors influencing the outcome of nosocomial bloodstream infections. A six year validated, population-based model. Clin Infect Dis 1997;24:1068-78.
82. Wenzel RP, Thompson RL, Landry SM. Hospital-acquired infection in intensive care unit patients: an overview with emphasis on epidemics. Infect Control 1983;4:371.
83. Brun-Buisson C, Doyon F, Carlet J. Bacteremia and severe sepsis in adults: a multicenter prospective survey in ICUs and wards of 24 hospitals. Am J Respir Crit Care Med 1996;154:617-24.
84. Valles J, Leon C, Alvarez-Lerma F. Nosocomial bacteremia in critically ill patients: a multicenter study evaluating epidemiology and prognosis. Clin Infect Dis 1997;24:387-95.
85. Edgeworth JD, Treacher DF, Eykyn SJ. A 25-year study of nosocomial bacteremia in an adult intensive care unit. Crit Care Med 1999;27:1421-8.
86. Jarvis WR, Martone WJ. Predominant pathogens in hospital infections. J Antimicrob Chemother 1992;29:19-24.
87. Puzniak L, Teutsch S, Powderly W, Polish L. Has the epidemiology of nosocomial candidaemia changed? Infect Control Hosp Epidemiol 2004;25:628-33.
88. Hospital Infections Program, National Center for Infectious Diseases, Center for Disease Control and Prevention. National Nosocomial Infections Surveillance (NNIS) report, data summary from January 1990-May 1999, issued June 1999. Am J Infect Control 1999;27:520-32.
89. Peres-Bota D, Rodriguez-Villalobos H, Dimopoulos G, Melot C, Vincent JL. Potential risk factors for infection with Candida spp. in critically ill patients. Clin Microbiol Infect 2004;10:550-5.
90. Nguyen MH, Peacock JE Jr, Morris AJ, Tanner DC, Nguyen ML, Snydman DR, et al. The changing face of candidaemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med 1996;100:617-23.
91. Pfaller MA, Jones RN, Doern GV. Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998. Antimicrob Agents Chemother 2000;44:747-51.
92. Trick WE, Fridkin SK, Edwards JR, Hajjeh RA, Gaynes RP. National Nosocomial Infections Surveillance System Hospitals. Secular trend of hospital-acquired candidaemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 2002;35:627-30.
93. Diekema DJ, Messer SA, Brueggemann AB, Coffman SL, Doern GV, Herwaldt LA, et al. Epidemiology of candidaemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study. J Clin Microbiol 2002;40:1298-302.
94. Pfaller MA, Diekema DJ, Jones RN, Sader HS, Fluit AC, Hollis RJ, et al. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibility to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY Antimicrobial Surveillance Program. J Clin Microbiol 2001;39:3254-9.
95. Berrouane YF, Herwaldt LA, Pfaller MA. Trends in antifungal use and epidemiology of nosocomial yeast infections in a university hospital. J Clin Microbiol 1999;37:531-7.
96. Collin B, Clancy CJ, Nguyen MH. Antifungal resistance in non-albicans Candida species. Drug Resist 1999;3:9-14.
97. Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-Moya L, Smietana J, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002;347:2020-9.